Comment on Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans

Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans

With the pandemic in the past, the Cambridge-based biotech company has struggled to maintain success, now announcing it will cut 20% of its R&D budget by 2027. Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over the next three years, a result of low sales projections and poor vaccine sales.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News